Gaucher's Disease | Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients With Gaucher's Disease

Gaucher's Disease research study

What is the primary objective of this study?

OBJECTIVES: I. Determine the efficacy of alendronate sodium in treating osteopenia (generalized bone density and focal bone lesions) in patients with Gaucher's disease.

Who is eligible to participate?

PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Diagnosis of type 1 Gaucher's disease enzymatically proven to have acid beta glucosidase deficiency Must have been on stable dose (8-60 U/kg/every 2 weeks) of alglucerase enzyme therapy (Cerezyme or Ceredase) for at least 24 months Lumbar spine bone density below the mean for age, sex, and race --Prior/Concurrent Therapy-- At least 6 months since prior medications that directly affect skeletal metabolism including, but not limited to, bisphosphonates, calcitonin, parathyroid hormone, or estrogen --Patient Characteristics-- Renal: No chronic renal failure; No recurrent renal stones Esophageal: No history of dysphagia; No frequent heartburn; No esophagitis requiring treatment Other: No untreated hyperthyroidism or hypothyroidism; No concurrent hyperparathyroidism; No concurrent malignancy; No history of alcohol or drug abuse; Not pregnant; Negative pregnancy test; Fertile patients must use effective contraception

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Gaucher's Disease


Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:alendronate sodium

Drug:calcium carbonate


Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

Study Status


Start Date: October 1998

Completed Date: September 2002

Phase: Phase 2

Type: Interventional


Primary Outcome:

Secondary Outcome:

Study sponsors, principal investigator, and references

Principal Investigator: Richard J. Wenstrup

Lead Sponsor: Children's Hospital Medical Center, Cincinnati


More information:

Discuss Fosamax